Skip to main content

Leadership

News Release

Printer Friendly Version View printer-friendly version
<< Back
Emergent BioSolutions to Present at November Investor Conferences

ROCKVILLE, Md.--(BUSINESS WIRE)--Oct. 29, 2007--Emergent BioSolutions Inc. (NYSE:EBS), announced today that company management will be presenting at two investor conferences during the month of November. The November conferences are:

  • JPMorgan Ninth SMid Cap Conference
    Four Seasons Hotel
    Boston, MA.
    November 5, 2007
    Presentation Time: 1:20 pm Eastern
  • Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
    New York Palace Hotel
    New York, NY.
    November 7, 2007
    Presentation Time: 11:50 am Eastern

During these presentations, senior management will provide a corporate overview, including a discussion of product development programs, recent corporate activities and financial performance.

Webcasts of each of these presentations will be available both live and by replay. To access either the live or archived webcast for either presentation, please proceed to www.emergentbiosolutions.com, click on the "Investors" link and proceed to the "Webcasts & Presentations" section, beginning on the day of the specific presentation.

An archived replay of each webcast will be available 24 hours after the live presentation.

About Emergent BioSolutions Inc.

Emergent BioSolutions Inc. is a biopharmaceutical company dedicated to one simple mission--to protect life. We develop, manufacture and commercialize immunobiotics, consisting of vaccines and therapeutics that assist the body's immune system to prevent or treat disease. Our biodefense business focuses on immunobiotics for use against biological agents that are potential weapons of bioterrorism and biowarfare. Our marketed product, BioThrax(R) (Anthrax Vaccine Adsorbed), is the only vaccine approved by the U.S. Food and Drug Administration for the prevention of anthrax disease. Our commercial business focuses on immunobiotics for use against infectious diseases and other medical conditions that have resulted in significant unmet or underserved public health needs. More information on the company is available at www.emergentbiosolutions.com.

CONTACT: Emergent BioSolutions Inc.
Investors:
Robert G. Burrows
Vice President, Investor Relations
301-795-1877
BurrowsR@ebsi.com
or
Media:
Tracey Schmitt
Director, Corporate Communications
301-795-1800
SchmittT@ebsi.com

SOURCE: Emergent BioSolutions Inc.